[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brugada-syndrome-brs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brugada-syndrome-brs":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,54,80,106,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100641518","prospective-multicentre-observational-registry-of-peri-procedural-anaesthesia-sedation-and-related-medication-exposure-in-patients-with-brugada-syndrome-100641518",false,"NCT07655102","Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome","BRUGADA-ANAESTHESIA Registry: Prospective Multicentre Observational Registry of Peri-procedural Anaesthesia, Sedation and Related Medication Exposure in Patients With Brugada Syndrome","PROSP_BRUGANAE","Patients should match all the inclusion criteria to be entered for data collection:\n\n* Documented type 1 Brugada ECG pattern (spontaneous, fever-related, or induced by sodium-channel blocker challenge\u002Fother recognised provocation test) with a diagnosis considered compatible with Brugada syndrome by the treating cardiology team.\n* Undergoing general anaesthesia, monitored sedation, loco-regional anaesthesia for any surgical, diagnostic, interventional, obstetric or other non-surgical procedure (including epidural analgesia for labour and sedation for endoscopy).\n\nPatients with one or more exclusion criteria will not be included for data collection and analysis:\n\n* No documented type 1 Brugada ECG pattern, uncertain diagnosis without sufficient supporting data.\n* Refusal to participate in the study.","ALL",{"count":19,"type":20},200,"ESTIMATED","30 Days","OBSERVATIONAL","The goal of this observational study is to evaluate the perioperative risk of malignant ventricular arrhythmias in adult patients diagnosed with Brugada Syndrome undergoing anaesthetic procedures. Brugada Syndrome is a rare inherited cardiac condition associated with an increased risk of life-threatening arrhythmias, and perioperative management remains challenging due to limited high-quality evidence.\n\nThe main questions it aims to answer are:\n\n* What is the incidence of malignant ventricular arrhythmias during anaesthesia and up to 30 days after the procedure?\n* Are anaesthetic drugs traditionally considered \"non-recommended\" associated with an increased risk of perioperative arrhythmic events?\n\nResearchers will also explore the relative contribution of anaesthetic drugs versus perioperative physiological factors (e.g., haemodynamic changes, fever, bradycardia) in triggering arrhythmias.\n\nParticipants will:\n\n* Undergo anaesthetic procedures (general, locoregional, or sedation) as part of routine clinical care\n* Have clinical data collected prospectively from electronic medical records during the perioperative period\n* Be followed for 30 days after the procedure to assess outcomes, including arrhythmias, complications, ICU admission, and mortality\n\nThis is a multicentre, prospective observational registry, and no additional interventions or changes to standard clinical practice will be performed.",[25,26,27,28],"Brugada Syndrome (BrS)","Ventricular Arrhythmia","Anesthesia","Sedation",[30,31,27,32,33,34,35,36,37,38,39,40],"Brugada Syndrome","Anaesthesia","Perioperative Care","Ventricular Arrhythmias","Cardiac Arrhythmias","Perioperative Risk","Anesthetic Drugs","Propofol","Sodium Channel Blockers","Observational Registry","Multicentre Study","NOT_YET_RECRUITING","2026-06-12",{"date":44,"type":45},"2026-06-17","ACTUAL",{"date":47,"type":20},"2026-07-20",{"date":49,"type":20},"2028-12-20",{"name":51,"class":52},"Hospital Clinic of Barcelona","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100620979","analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav15-autoantibodies-in-patients-with-metastatic-tumors-100620979","NCT07364656","Analysis of the Presence and Cardiac Functional Effects of Anti-NaV1.5 Autoantibodies in Patients With Metastatic Tumors","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic\n* Patients already receiving first-line therapy with a confirmed diagnosis of breast or colorectal cancer, either metastatic or non-metastatic\n* Signed informed consent\n\nExclusion Criteria:\n\n* Clinically significant cardiovascular diseases (atrial fibrillation, congestive heart failure, cardiomyopathies, or inherited arrhythmic syndromes)\n* Known autoimmune diseases or immunodeficiencies\n* Use of high-dose immunosuppressive drugs or other experimental treatments that could interfere with the assessment of study endpoints",{"count":61,"type":20},196,"INTERVENTIONAL",[64],"NA","The overall aim of this study is to identify and characterize anti-NaV1.5 autoantibodies in patients with metastatic breast and colorectal cancer. These tumors are characterized by the presence of a specific target structure (called nNaV1.5) against which antibodies are produced. These antibodies may cross-react with a similar structure (called NaV1.5) that is found in the heart. This could affect channel function and increase the risk of arrhythmias.",[25,67,68,69,70],"Breast Cancer Females","Colon Cancer","ECG Abnormalities","Autoantibodies Screening","2026-01-16",{"date":73,"type":45},"2026-01-23",{"date":75,"type":20},"2026-01",{"date":77,"type":20},"2026-12",{"name":79,"class":52},"IRCCS Policlinico S. Donato",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":62,"phases":90,"briefSummary":92,"conditions":93,"keywords":94,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":53},"100604235","phase-2-empagliflozin-as-a-potential-therapeutic-solution-for-patients-with-brugada-syndrome-100604235","NCT07146880","Empagliflozin as a Potential Therapeutic Solution for Patients With Brugada Syndrome","Inclusion Criteria:\n\n1. Patients diagnosed with Brugada syndrome and aged 18-99 years with spontaneous type 1 ECG, normal structural heart and patent coronary artery\n2. Obtain written informed consent for participation in the clinical trial\n\nExclusion Criteria:\n\n1. Individuals with type 1 ECG pattern only observed with fever-induced or drug-induced were excluded from this exploratory study.\n2. Current or prior use of an SGLT2 inhibitor within 12 weeks before screening or randomization\n3. Known allergy or hypersensitivity to any SGLT2 inhibitor\n4. History of ketoacidosis\n5. Symptomatic hypotension or systolic blood pressure \\\u003C90 mmHg or \\>180 mmHg\n6. Heart failure\n7. Acute myocardial infarction\n8. ALT or AST \\>3× ULN at screening\n9. Impaired renal function (eGFR \\\u003C20 mL\u002Fmin\u002F1.73 m² \\[MDRD\\]), requiring dialysis, or functioning kidney transplant at screening\n10. Pregnancy, nursing, or planning pregnancy during the trial\n11. Enrollment in another investigational drug or device study or completion of such a study within the last 30 days\n12. Known poor adherence to clinic visits or prescribed medications\n13. Medical conditions that may limit trial participation, including severe respiratory disease, history of cancer with metastasis in the past four years (excluding non-melanoma skin cancer), or recent alcohol\u002Fsubstance misuse","18 Years","99 Years",{"count":89,"type":20},10,[91],"PHASE2","The goal of this clinical trial is to learn if Empagliflozin works to treat Brugada syndrome patients by affecting their electrocardiographic (ECG) patterns, and to evaluate its safety.\n\nThe main questions it aims to answer are:\n\n* Does Empagliflozin improve specific electrocardiogram (ECG) patterns in Brugada syndrome patients, specifically by observing the change in J-point elevation recorded in V1 and V2 leads at the 4th, 3rd, and 2nd intercostal spaces (ICSs)? A responder is defined as a decrease in J-point elevation of ≥1 mm.\n* What adverse events do participants experience when taking Empagliflozin, including hypotension, acute renal failure, hepatic injury, ketoacidosis, hypoglycemic events, urinary tract infections, genital infections, bone fractures, and events leading to lower limb amputation?\n\nResearchers will compare each participant's ECG changes before and after three months of Empagliflozin treatment to assess its efficacy\n\nParticipants will:\n\n* Take Empagliflozin once daily, starting at 10 mg. The dose will be increased to 25 mg at monthly follow-ups if participants are non-responders based on ECG ST-segment morphology. The total treatment period is three months.\n* Visit the outpatient clinic monthly for three months of treatment to monitor efficacy and safety. The overall trial period, including screening, treatment, and follow-up, comprises five scheduled visits.\n* Undergo a series of check-ups and tests, including:\n\n  * 12-lead electrocardiography (ECG) recordings.\n  * Monitoring and documentation of adverse events.\n  * Blood and urine tests, such as complete blood count (CBC), liver function tests (AST\u002FALT), renal function tests (BUN\u002Fcreatinine), electrolytes (sodium\u002Fpotassium\u002Fcalcium\u002Fmagnesium\u002Falbumin), urinalysis, fasting glucose, HbA1c, and ketone measurements.",[25],[25,95,96],"Sodium-glucose cotransporter 2 inhibitors (SGLT-2i)","Empaflifozin","2025-09-07",{"date":99,"type":45},"2025-09-12",{"date":101,"type":20},"2025-09-15",{"date":103,"type":20},"2027-09-21",{"name":105,"class":52},"National Taiwan University Hospital",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":17,"minAge":86,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":53},"100592035","unmasking-concealed-arrhythmia-syndromes-100592035","NCT06988189","Unmasking Concealed Arrhythmia Syndromes","UCAS","Inclusion Criteria:\n\n* Adults willing to take part\n* Able to give consent\n\nExclusion Criteria:\n\n* Unable to give consent\n* Children age \\\u003C 18 years and adults \\> 100 years old",true,"100 Years",{"count":19,"type":20},"This study seeks to evaluate whether using non-invasive electrocardiograph (ECG) techniques, including long term ECG monitoring with wearable ECGs, can improve the detection of concealed Brugada syndrome.",[118,25],"Brugada ECG Patterns",[120,121,122,123,124],"Brugada syndrome","Ambulatory ECG","Wearable ECG","Long term continuous monitoring","AI ECG","RECRUITING","2025-05-16",{"date":128,"type":45},"2025-05-23",{"date":130,"type":45},"2024-09-09",{"date":132,"type":20},"2026-11",{"name":134,"class":52},"Imperial College London",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":53},"100565880","genlab-unveiling-the-genetic-landscape-of-brugada-syndrome-novel-biomarker-discovery-for-precise-diagnosis-100565880","NCT06647927","GenLab: Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis","Unveiling the Genetic Landscape of Brugada Syndrome: Novel Biomarker Discovery for Precise Diagnosis","GenLaB","Inclusion Criteria:\n\n* Age \\> 18 years\n* Patients affected by Brugada Syndrome\n* Patients who signs the Informed Consent\n\nExclusion Criteria:\n\n* None",{"count":144,"type":20},350,"This research makes several significant contributions to the field of BrS. It employs advanced genetic sequencing techniques to develop a genetic signature to improve the accuracy and efficiency of BrS diagnosis. The identification of specific biomolecular profiles and genetic signatures enhances our understanding of the syndrome's molecular mechanisms, facilitating targeted therapies and refined risk stratification. These advancements optimize patient care by enabling personalized treatment plans and risk assessment. Overall, this research adds value by advancing diagnostic methods, providing molecular insights, optimizing patient care, and positively impacting public health outcomes in BrS.",[25],"2025-05-13",{"date":149,"type":45},"2025-05-14",{"date":151,"type":45},"2024-12-02",{"date":153,"type":20},"2026-09",{"name":79,"class":52}]